• Laboratorios Richmond reported net eligible sales of ARS 5.05 billion for products tied to amortization terms under its Global Program of Obligaciones Negociables, Serie III, covering April 1 to June 30, 2026.
• Monthly eligible sales were ARS 1.58 billion in April, ARS 1.83 billion in May, and ARS 1.64 billion in June.
• May sales rose 16.16% from April.
• June sales fell 10.32% from May.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laboratorios Richmond SACIF published the original content used to generate this news brief on July 27, 2026, and is solely responsible for the information contained therein.